ClinicalTrials.gg
CompletedNCT00606450PSOR-003Updated Apr 24, 2020

Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis

A Phase 2 interventional study of CC-10004 and CC-10004 in Psoriasis, sponsored by Amgen. Completed at 31 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Apr 2006, registered Jan 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
11th of 44
260 · median 103
Started
2006
the only one that year
Phase 2
10 of 44
none open now
Registered
3rd of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 11th largest by enrollment, is the only one that started in 2006, is one of 10 in phase 2, and was the 3rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The information obtained from the study will aid in the design of future clinical trials and to establish the safety and efficacy of CC-10004.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • plaque psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must understand and voluntarily sign and form
  • Must be in good health as judged by the investigator
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Must have greater than or equal to a 6 month history of moderate-to-severe plaque-type psoriasis
  • Must have a Psoriasis Area and Severity Index (PASI) score greater than or equal to 10 and Body Surface Area (BSA) greater than or equal to 10%
  • Must meet specific laboratory criteria
  • Must be a candidate for photo/systemic therapy
  • Women of must have a negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Must not have underlying disease processes
  • Must not be pregnant or lactating females
  • Must not have any condition, including lab abnormalities, which places the subject at unacceptable risk if the subject were to participate in the study or confounds the ability to interpret data from the study
  • Must not have a history of active mycobacterium tuberculosis infection within 3 years prior to the screening visit
  • Must not have a history of incompletely treated active of latent mycobacterium tuberculosis infection
  • Must not have a know history of exposure to an infectious case of mycobacterium tuberculosis within 2 years prior to the screening visit
  • Must not be an immigrant form a high-incidence country for mycobacterium tuberculosis disease within 2 years prior to the screening visit
  • Must not have current erythrodermic, guttate, or pustular psoriasis
  • Must not have a clinical history of failure to adequately respond to treatment in the investigator's opinion to one or more treatment courses of cyclosporine or the following biologic therapies: alefacept, etanercept, efalizumab, infliximab or adalimumab
  • Must not use topical therapy within 14 days of randomization
  • Must not use systemic therapy for psoriasis within 28 days of randomization
  • Must not use phototherapy within 28 days of randomization
  • Must not use adalimumab or infliximab within 3 months of randomization
  • Must not use etanercept or efalizumab within 56 days of randomization
  • Must not use alefacept within 6 months of randomization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    20 mg Apremilast daily

    20 mg of CC-10004 daily

    Drug: CC-10004

  • Experimental
    20mg Apremilast twice daily

    CC-10004 twice daily

    Drug: CC-10004

  • Placebo comparator
    Placebo

    Placebo arm

    Drug: Placebo

Interventions

  • 20 mg CC-10004 taken 1 time per day for 12 weeks

    Also known as: Apremilast

  • 20 mg of CC-10004 taken 2 times per day for 12 weeks

    Also known as: Apremilast

  • DrugPlacebo

    matching placebo taken either 1 or 2 times per day for 12 weeks

06

What researchers measure

Primary outcomes

  1. To compare the clinical efficacy of 2 oral doses of CC-10004 with placebo when taken for 12 weeks in subjects with moderate-to-severe plaque-type psoriasis

    Time frame: 12 weeks

Secondary outcomes

  1. To evaluate the safety of CC-10004 compared with placebo in subjects with moderate-to-severe placque-type psoriasis

    Time frame: 12 weeks

  2. To evaluate the effects of CC-10004 compared to placebo on the quality of life in subjects with moderate-to-severe plaque-type psoriasis.

    Time frame: 12 weeks

07

Study locations

31 sites
  • Division of Dermatology and Cutaneous Science
    Edmonton, Alberta, Canada
  • Division of Dermatology
    Vancouver, British Columbia, Canada
  • Duronder C.P. Inc
    Moncton, New Brunswick E1C 8X3, Canada
  • Eastern Canada Cutaneous Research Associates
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Ultranova Skincare
    Barrie, Ontario L4M 6L2, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1V6, Canada
  • The Lynde Center for Dermatology
    Markham, Ontario L3P 7N8, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B3Z7, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario L3P 7N8, Canada
  • Innovaderm
    Montreal, Quebec H2K 4L5, Canada
  • Dr Yves Poulin
    Quebec City, Quebec G1V 4X7, Canada
  • Department of Dermatology
    Brno, Czechia
  • Department of Dermatology
    Hradec Kralove, Czechia
  • Department of Dermatovererology
    Olomouc, Czechia
  • Department of Dermatovererology
    Praha, Czechia
  • Depart of Dermatology
    Usti nad Labem, Czechia
  • Celgene Clinical Site
    Ausburg, Germany
  • Celgene Clinical Site
    Berlin, Germany
  • Department of Dermatologie and Venerology
    Dresden, Germany
  • Department of Dermatology and Venerology
    Frankfurt Main, Germany
  • Celgene Clinical Site
    Hamburg, Germany
  • Celgene Clinical Site
    Heidelberg, Germany
  • Celgene Clinical Site
    Herborn, Germany
  • Celgene Clinical Site
    Homburg, Germany
  • Celgene Clinical Site
    Leipzig, Germany
  • Celgene Clinical Site
    Mannheim, Germany
  • Celgene Clinical Site
    Munster, Germany
  • Celgene Clinical Site
    Salzwedel, Germany
  • Celgene Clinical Site
    Schwerin, Germany
  • Celgene Clinical Site
    Wiesbaden, Germany
  • Celgene Clinical Site
    Wurzburg, Germany
08

References and documents

Publications

  • Papp KA, Kaufmann R, Thaci D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83. doi: 10.1111/j.1468-3083.2012.04716.x. Epub 2012 Oct 3. PubMed 23030767 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2006 to primary completion in Feb 2007, 10 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2008
First posted
Feb 4, 2008
StartActual
Apr 1, 2006
Primary completionActual
Feb 1, 2007
CompletionActual
May 1, 2007
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00606450
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 4, 2008
Start date
Apr 1, 2006
Primary completion
Feb 1, 2007
Completion
May 1, 2007
Last update
Apr 24, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion